Centrally Acting Melanocortins vs. Peripheral Options: A Medical Timeline
Therapeutic strategies for female sexual health have evolved through distinct conceptual phases over recent years. Clinicians and researchers have shifted from viewing symptoms solely through localized physiology to evaluating how the central nervous system and peripheral tissues interact. A key milestone in understanding this landscape arrived in a 2022 review titled Pharmacotherapy for Sexual Dysfunction in Women, published in Current psychiatry reports. This timeline explainer details how therapeutic mechanisms compare across central and peripheral pathways, why diagnostic criteria remain debated, and what the clinical literature actually demonstrates.
The Diagnostic Background and the DSM-5 Controversy
Before examining pharmacotherapies, understanding the diagnostic context is essential. Diagnostic frameworks categorize conditions such as hypoactive sexual desire disorder (HSDD), female sexual arousal disorder (FSAD), and genitopelvic pain/penetration disorder (GPPD). However, classification systems have generated significant clinical discussion.
A primary issue highlighted in the 2022 review is the controversy surrounding the DSM-5 criteria. The DSM-5 revised its framework by combining HSDD and FSAD into a single diagnostic category. The authors of the review emphasize that this merger provides a less accurate characterization of what are clinically distinct conditions. Furthermore, grouping them together may inadvertently hinder patients from accessing treatments that have demonstrated effectiveness for these individual conditions. Accurately distinguishing between centrally driven desire concerns and arousal or physical discomfort remains a major focus of ongoing sexual medicine.
Centrally Acting Agents: Melanocortins and Neurotransmitter Modulators
Centrally acting medications target receptors within the brain to address pathways associated with sexual response. Rather than targeting local genital blood flow directly, these therapies influence neural circuits that regulate desire and central arousal processing.
Within this category, melanocortin receptor agonists represent a significant mechanistic pathway. The review highlights clinical updates regarding the efficacy and safety of bremelanotide for the treatment of HSDD. In addition to melanocortin therapies, the paper tracks updates to other central treatments, noting the removal of the flibanserin alcohol REMS (Risk Evaluation and Mitigation Strategy) requirement. The authors also document ongoing technical advances in drug development, specifically the emergence of new technologies designed to enhance bioavailability and facilitate targeted brain delivery for centrally acting compounds.
Peripheral and Hormonal Interventions
In contrast to agents that act primarily within the central nervous system, peripheral pharmacotherapies focus on local tissue health, hormonal balances, and physical comfort. These options address conditions such as genitopelvic pain/penetration disorder and the physical changes that occur across different reproductive life stages.
The 2022 review outlines several critical updates regarding peripheral and systemic hormonal approaches:
- Vaginal Estrogen: Updated evidence reinforces the efficacy and safety of localized vaginal estrogen for managing the genitourinary syndrome of menopause, directly improving tissue integrity and reducing discomfort.
- Testosterone Therapy: The publication notes the release of an international global position statement outlining clear guidelines for testosterone therapy in women.
- Processes of Care: Clearer clinical frameworks have delineated the specific process of care for both premenopausal and postmenopausal women diagnosed with HSDD.
Timeline of Key Clinical Developments
The evolution of treatments for female sexual dysfunction can be traced through several foundational shifts examined by the 2022 review:
- Establishment of Diagnostic Standards: Ongoing re-evaluation of DSM-5 diagnostic criteria, balancing combined categories against the distinct realities of HSDD and FSAD.
- Consensus on Hormonal Prescribing: Formalization of evidence via the global position statement on systemic testosterone therapy for female populations.
- Refinement of Localized Therapies: Clarification of the clinical profile of vaginal estrogen for postmenopausal genitourinary symptoms.
- Targeted Central Approvals: Data updates assessing bremelanotide for HSDD alongside regulatory adjustments like the removal of the flibanserin alcohol REMS.
- Delivery Innovations: Formulation research directed toward improving bioavailability and central delivery pathways for neuroactive compounds.
Study Design, Boundaries, and Limitations
When evaluating these comparative mechanisms, it is critical to interpret the source material accurately. The publication in Current psychiatry reports is a narrative review article rather than an original, blinded clinical trial. Its design serves to summarize and contextualize broader research trends, regulatory updates, and expert position papers rather than to generate new quantitative outcome figures.
Because it is a single review article, it provides an overview of the field at a specific point in time. Readers must avoid overstating its conclusions as definitive proof that one therapeutic class is universally superior to another. The authors stress that female sexual dysfunction encompasses a broad range of pharmacological, physiological, and psychological dimensions. Effective clinical management relies on tailoring interventions to an individual's specific symptoms, unique preferences, and the potential balance of benefits and risks under medical supervision, as explored in discussions on medical treatments for female arousal concerns.
Sources
Published October 30, 2026. Sources are linked in the text. See our Medical Disclaimer.